2257.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 05:02):

Stats
Šios dienos apimtis	148 800
Vidutinė apimtis	3.44M
Rinkos kapitalizacija	629.24M
EPS	HKD0 ( 2023-08-31 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.840
ATR14	HKD0.0740 (1.02%)

Tūris Koreliacija

Ilgas: 0.18 (neutral)

Trumpas: -0.39 (neutral)

Signal:(41.581) Neutral

Sirnaomics Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sirnaomics Ltd. Koreliacija - Valiuta/Žaliavos

-0.28
( neutral )

0.11
( neutral )

-0.76
( moderate negative )

-0.74
( moderate negative )

0.57
( weak )

0.53
( weak )

Sirnaomics Ltd. Finansinės ataskaitos

Annual	2023
Pajamos:	HKD40 000.00
Bruto pelnas:	HKD40 000.00 (100.00 %)
EPS:	HKD-1.030

FY	2023
Pajamos:	HKD40 000.00
Bruto pelnas:	HKD40 000.00 (100.00 %)
EPS:	HKD-1.030

FY	2022
Pajamos:	HKD0
Bruto pelnas:	HKD0 (0.00 %)
EPS:	HKD-1.160

Financial Reports:

No articles found.

Sirnaomics Ltd.

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.